10-K/A: Creative Medical Technology Holdings Files Amendment to 10-K to Include Clawback Policy

Creative Medical Technology Holdings files an amendment to its annual report to include a clawback policy in compliance with Nasdaq listing rules.

Summary

• Creative Medical Technology Holdings filed Amendment No. 2 on Form 10-K/A to its Annual Report for the year ended December 31, 2024.
• The amendment was filed solely to include Exhibit 97.1, the Clawback Policy, as an exhibit to the original filing in accordance with Nasdaq Listing Rule 5608.
• No other changes were made to the original filing, and the amendment does not reflect events that may have occurred subsequent to the original filing date.
• The company had 2,535,897 shares of common stock outstanding as of March 14, 2025.
• The aggregate market value of the registrant's common stock held by non-affiliates as of June 30, 2024, was $5,151,785.
• The clawback policy was approved on April 4, 2025, with retroactive effect to December 1, 2023.
• The policy applies to all incentive-based compensation received by executive officers after beginning service and while the company has a class of securities listed on Nasdaq.
• The policy covers the three completed fiscal years immediately preceding the date that the company is required to prepare a restatement, plus any transition period.
• The company must recover any erroneously awarded compensation in the event of a restatement, except under specific circumstances where recovery would be impracticable.
• The company will take steps to implement an agreement to the clawback policy by all current and future executive officers.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing. The inclusion of a clawback policy is generally viewed positively as it aligns management interests with shareholder value.

Positives

• The company is implementing a clawback policy to comply with Nasdaq listing rules, demonstrating a commitment to ethical standards and regulatory compliance.
• The clawback policy has a retroactive effect to December 1, 2023, providing a longer period of coverage.

Risks

• The company may face challenges in determining the amount of erroneously awarded compensation, especially for incentive-based compensation based on stock price or total shareholder return.
• Enforcement of the clawback policy could lead to disputes with current or former executive officers.

Future Outlook

The company will continue to comply with federal securities laws and Nasdaq requirements regarding the clawback policy and disclosures.

Industry Context

Clawback policies are becoming increasingly common among publicly traded companies due to regulatory requirements and investor expectations for accountability in executive compensation.

Comparison to Industry Standards

• Many companies listed on Nasdaq and other major exchanges have adopted clawback policies to comply with Rule 5608.
• These policies generally aim to recover incentive-based compensation from executive officers in the event of a financial restatement.
• The specifics of each policy, such as the scope of covered officers and the methods of recovery, can vary.

Corporate Governance

Stakeholder Impact

• Shareholders: The clawback policy provides additional protection for shareholder value by ensuring accountability for financial misstatements.
• Executive Officers: The policy may impact executive compensation in the event of a financial restatement.
• Employees: The policy reinforces the company's commitment to ethical standards and regulatory compliance.

Next Steps

• The company will implement agreements with executive officers to ensure compliance with the clawback policy.
• The company will monitor and comply with any changes to Rule 5608 or other applicable laws and regulations.

Key Dates

Keywords

clawback policy, executive compensation, financial restatement, Nasdaq, Form 10-K/A, Creative Medical Technology Holdings